Biotherapeutics Company to Receive lab Space,
Mentoring and Other Benefits
THOUSAND
OAKS, Calif., Jan. 6, 2023
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist
Institute today announced that Nammi Therapeutics has been awarded
the third Amgen Golden Ticket in Southern
California. Nammi Therapeutics will receive one year of lab
space at BioLabs LA at The Lundquist Institute (TLI) as well as
additional facility benefits and connections to Amgen's scientific
and business leaders.
The Amgen Golden Ticket winner was chosen by a team of Amgen
scientific leaders at a virtual pitch event. Five finalists pitched
their business plans before Amgen's internal committee that
evaluated the strength and novelty of their scientific rationale,
subject matter expertise and business plan viability. This is
the third Amgen Golden Ticket awarded to help accelerate life
science startups in Southern
California.
Perspectives on announcement:
- "As we announce our third Southern California Golden Ticket
winner, it's exciting to see how Amgen's partnership with BioLabs
LA at The Lundquist Institute has already made an impact on
scientific research in the greater Los
Angeles area, helping to accelerate the growth and
development of several life-science startups. We look forward to
extending this opportunity to Nammi Therapeutics and their exciting
work in immuno-oncology." – Alan
Russell, Ph.D., vice president of Biologic Therapeutic
Discovery at Amgen
- "It has been an honor to work with BioLabs, the Lundquist
Institute, and Amgen on the third consecutive Golden Ticket event.
After witnessing the success of the first two award recipients
(Karma Biotechnologies and Diadem Therapeutics), we cannot wait to
see what progress this collaboration with Nammi Therapeutics drives
next." – Lindsay Bourgeois, site
director, BioLabs LA
- "Nammi is honored to have been chosen as the winner of the
Amgen-BioLabs Golden Ticket Award. The material support for our
organization is very helpful and having the promise of the Nammi
immuno-oncology platform technologies to improve the lives of
cancer patients recognized by a leader in the field such as Amgen
is even more rewarding. We look forward to working with Amgen and
BioLabs as we advance our lead programs and grow our organization."
– David R. Stover, Ph.D., president
and CEO, Nammi Therapeutics
Amgen supports life science startups through Golden Ticket
awards and affiliated engagement in other biotech innovation hubs,
including San Francisco,
Boston, Singapore and Toronto. Nammi Therapeutics is the
30th Golden Ticket winner since program inception in
2014.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has
reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow
Jones Industrial Average and is also part of the Nasdaq-100 index.
In 2022, Amgen was named one of the "World's Best Employers" by
Forbes and one of "America's 100 Most Sustainable Companies" by
Barron's.
For more information, visit Amgen.com and follow us
on Twitter, LinkedIn, Instagram, TikTok and
YouTube.
About The Lundquist Institute: Research with reach™
The Lundquist Institute is an engine of innovation with a global
reach and a 69-year reputation of improving and saving lives. With
its new medical research building, its state-of-the-art incubator,
"BioLabs at The Lundquist," existing laboratory and support
infrastructure, and the development of a new 15-acre business tech
park, the Lundquist Institute serves as a hub for the Los Angeles area's burgeoning biotech scene.
The research institute has over 100 principal investigators (PhDs,
MDs, and MD/PhDs) working on more than 600 research studies,
including therapies for numerous, and often fatal orphan diseases.
Find out more at https://lundquist.org.
About BioLabs LA at The Lundquist
Institute
Encompassing the entire third floor of The
Lundquist Institute's new Medical Research Lab building, BioLabs LA
offers shared lab facilities designed for high-potential,
early-stage life since companies. BioLabs creates co-working
communities that pair premium, fully equipped and supported lab and
office space with unparalleled access for entrepreneurs to
networking, industry partners, and capital. Find out more
at https://www.biolabs.io/la.
About Nammi Therapeutics, Inc.
Nammi Therapeutics,
Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and
products that selectively activate anti-tumor immunity within the
tumor microenvironment while minimizing systemic activation.
By reducing systemic activation of the immune system, Nammi expects
to improve safety and enhance the ability to combine multiple
immune modulators. Nammi's lead product candidate, QXL138AM, is a
Masked Immunocytokine (MIC) targeting a masked interferon to the
tumor antigen, CD138. In addition to the MIC platform, Nammi has
also developed a nanoparticle platform to deliver Immune Modulating
Prodrugs (IMPs) using their Nammisome technology. Multiple
Nammisome clinical candidates have also been selected for
development. Find out more at www.NammiRX.com.
CONTACT: Amgen, Thousand Oaks
Michael Strapazon, 805-313-5553
(media)
The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center
Keith B. Hoffman, Ph.D.,
310-974-9301, keith.hoffman@lundquist.org
BioLabs LA
Lindsay Bourgeois,
978-852-1081, lbourgeois@biolabs.io
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-and-biolabs-la-at-the-lundquist-institute-announce-nammi-therapeutics-to-receive-the-third-amgen-golden-ticket-301715686.html
SOURCE Amgen